单位：[1]Chinese Acad Med Sci & Peking Union Med Coll, China Japan Friendship Hosp, Dept Cardiol, Beijing, Peoples R China[2]Peking Univ, China Japan Friendship Sch Clin Med, Dept Cardiol, Beijing, Peoples R China[3]China Japan Friendship Hosp, Dept Pharm, Beijing, Peoples R China[4]China Japan Friendship Hosp, Ctr Resp Med, Dept Pulm Crit Care Med, Beijing, Peoples R China[5]China Japan Friendship Hosp, Dept Cardiol, Beijing, Peoples R China
National Science and Technology Major Project of China [2014ZX09303305]; Chinese Acad- emy of Medical Sciences Innovation Fund for Medical Sciences [2018-I2M-1-003]
第一作者单位：[1]Chinese Acad Med Sci & Peking Union Med Coll, China Japan Friendship Hosp, Dept Cardiol, Beijing, Peoples R China
共同第一作者：
通讯作者：
通讯机构：[1]Chinese Acad Med Sci & Peking Union Med Coll, China Japan Friendship Hosp, Dept Cardiol, Beijing, Peoples R China[2]Peking Univ, China Japan Friendship Sch Clin Med, Dept Cardiol, Beijing, Peoples R China[5]China Japan Friendship Hosp, Dept Cardiol, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Wang Zhe,Zhu Long-Yang,Yu Lu-Yao,et al.Real-world rivaroxaban use in fragile Asian patients with atrial fibrillation: The impact of plasma concentration on clinical outcomes[J].THROMBOSIS RESEARCH.2022,218:189-191.doi:10.1016/j.thromres.2022.08.027.
APA：
Wang, Zhe,Zhu, Long-Yang,Yu, Lu-Yao,Chen, Wen-Qian,Chen, Yi-Nong...&Sun, Yi-Hong.(2022).Real-world rivaroxaban use in fragile Asian patients with atrial fibrillation: The impact of plasma concentration on clinical outcomes.THROMBOSIS RESEARCH,218,
MLA：
Wang, Zhe,et al."Real-world rivaroxaban use in fragile Asian patients with atrial fibrillation: The impact of plasma concentration on clinical outcomes".THROMBOSIS RESEARCH 218.(2022):189-191
